ANDA 72074, held by IGI Laboratories. Nalbuphine Hydrochloride.
As of Nov 22, 2026, ANDA 72074 (Nalbuphine Hydrochloride), held by IGI Laboratories, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Nalbuphine Hydrochloride20MG/ML (20MG/ML) · solution;intramuscular, intravenous, subcutaneous | Nalbuphine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters